Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.3860
-0.0009 (-0.23%)
At close: Mar 13, 2026, 4:00 PM EDT
0.3890
+0.0030 (0.78%)
After-hours: Mar 13, 2026, 7:49 PM EDT
Mereo BioPharma Group Employees
Mereo BioPharma Group had 36 employees as of December 31, 2024. The number of employees increased by 3 or 9.09% compared to the previous year.
Employees
36
Change (1Y)
3
Growth (1Y)
9.09%
Revenue / Employee
$13,889
Profits / Employee
-$1,154,806
Market Cap
61.42M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 36 | 3 | 9.09% |
| Dec 31, 2023 | 33 | -3 | -8.33% |
| Dec 31, 2022 | 36 | -13 | -26.53% |
| Dec 31, 2021 | 49 | 11 | 28.95% |
| Dec 31, 2020 | 38 | -12 | -24.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Metagenomi Therapeutics | 124 |
| InflaRx | 74 |
| BeyondSpring | 40 |
| eXoZymes | 31 |
| LeonaBio | 26 |
| Entera Bio | 22 |
| Lipocine | 16 |
MREO News
- 11 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo Lawsuit - MREO - PRNewsWire
- 18 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo BioPharma Group plc Lawsuit - MREO - PRNewsWire
- 24 days ago - Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - PRNewsWire
- 24 days ago - Stockholders Who Lost Money Investing in Mereo BioPharma Group plc Should Contact Robbins LLP for Information About Recovering Their Losses from MREO - GlobeNewsWire
- 4 weeks ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma - Newsfile Corp
- 2 months ago - Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - These biotech stocks are getting hammered by shocking brittle-bone treatment study results - Market Watch
- 2 months ago - Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta - GlobeNewsWire